IPO - Profile

Terns Pharmaceuticals, Inc.

Health Care > Major Pharmaceuticals

TERN

Summary

We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Our programs are based on clinically-validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. The mechanisms of action targeted by our current drug candidates are the same mechanisms of action targeted by other drug candidates that have achieved clinical proof-of-concept in NASH clinical trials and have More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 7,500,000 Positive High 40.17%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 03 Feb, 2021

Offer 05 Feb, 2021

Look Ahead

Lock Up Expiry Aug 05, 2021

IPO Terms

Offer Price $17.00
Offer Size 7M

Market Sentiments

Stock Price